KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Raw Materials (2016 - 2017)

Amgen has reported Raw Materials over the past 5 years, most recently at $237.0 million for Q2 2017.

  • For Q2 2017, Raw Materials changed N/A year-over-year to $237.0 million; the TTM value through Jun 2017 reached $237.0 million, changed N/A, while the annual FY2016 figure was $225.0 million, 11.94% up from the prior year.
  • Raw Materials for Q2 2017 was $237.0 million at Amgen, up from $216.0 million in the prior quarter.
  • Over five years, Raw Materials peaked at $237.0 million in Q2 2017 and troughed at $198.0 million in Q4 2014.
  • A 5-year average of $214.4 million and a median of $216.5 million in 2013 define the central range for Raw Materials.
  • Biggest five-year swings in Raw Materials: decreased 8.76% in 2014 and later increased 11.94% in 2016.
  • Year by year, Raw Materials stood at $217.0 million in 2013, then fell by 8.76% to $198.0 million in 2014, then grew by 1.52% to $201.0 million in 2015, then rose by 11.94% to $225.0 million in 2016, then increased by 5.33% to $237.0 million in 2017.
  • Business Quant data shows Raw Materials for AMGN at $237.0 million in Q2 2017, $216.0 million in Q1 2017, and $225.0 million in Q4 2016.